279 related articles for article (PubMed ID: 15551739)
1. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Wixom CR; Albers EA; Weidner N
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
[TBL] [Abstract][Full Text] [Related]
2. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
[TBL] [Abstract][Full Text] [Related]
3. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract][Full Text] [Related]
4. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
Shen DH; Wang FH; Yu YZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
[TBL] [Abstract][Full Text] [Related]
6. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
7. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
[TBL] [Abstract][Full Text] [Related]
8. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.
Dandachi N; Dietze O; Hauser-Kronberger C
Lab Invest; 2002 Aug; 82(8):1007-14. PubMed ID: 12177239
[TBL] [Abstract][Full Text] [Related]
9. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
10. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M; Rasmussen BB
Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
[TBL] [Abstract][Full Text] [Related]
11. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.
Loring P; Cummins R; O'Grady A; Kay EW
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):194-200. PubMed ID: 15894935
[TBL] [Abstract][Full Text] [Related]
12. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
Arnould L; Denoux Y; MacGrogan G; Penault-Llorca F; Fiche M; Treilleux I; Mathieu MC; Vincent-Salomon A; Vilain MO; Couturier J
Br J Cancer; 2003 May; 88(10):1587-91. PubMed ID: 12771927
[TBL] [Abstract][Full Text] [Related]
13. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
14. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
Hauser-Kronberger C; Dandachi N
J Mol Histol; 2004 Aug; 35(6):647-53. PubMed ID: 15614619
[TBL] [Abstract][Full Text] [Related]
15. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
[TBL] [Abstract][Full Text] [Related]
16. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
17. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
18. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
19. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
García-Caballero T; Grabau D; Green AR; Gregory J; Schad A; Kohlwes E; Ellis IO; Watts S; Mollerup J
Histopathology; 2010 Mar; 56(4):472-80. PubMed ID: 20459554
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
